SAB BIO (NASDAQ: SABS) surged 31.91% in pre-market trading on July 21, 2025, rising to $3.39 from the prior close of $2.57.
The rally follows news that SABS secured $175 million in gross proceeds via an oversubscribed private placement, issuing Series B nonvoting convertible preferred stock.
The capital will fund the Phase 2b SAFEGUARD study of SAB-142 for Stage 3 autoimmune T1D and support general operations. Elevated trading volume accompanied the sharp price move.
